240 related articles for article (PubMed ID: 27941799)
1. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
[TBL] [Abstract][Full Text] [Related]
2. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
Vo K; Amarasinghe B; Washington K; Gonzalez A; Berlin J; Dang TP
Mol Cancer; 2011 Nov; 10():138. PubMed ID: 22074495
[TBL] [Abstract][Full Text] [Related]
3. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
4. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
[TBL] [Abstract][Full Text] [Related]
5. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
7. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.
Whelan JT; Kellogg A; Shewchuk BM; Hewan-Lowe K; Bertrand FE
J Cell Biochem; 2009 Aug; 107(5):992-1001. PubMed ID: 19479935
[TBL] [Abstract][Full Text] [Related]
8. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer.
Kim SJ; Lee HW; Baek JH; Cho YH; Kang HG; Jeong JS; Song J; Park HS; Chun KH
Oncogene; 2016 Jan; 35(2):251-60. PubMed ID: 25823029
[TBL] [Abstract][Full Text] [Related]
9. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
Nair JS; Sheikh T; Ho AL; Schwartz GK
Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
[TBL] [Abstract][Full Text] [Related]
10. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
[TBL] [Abstract][Full Text] [Related]
11. NOTCH and PTEN in prostate cancer.
Bertrand FE; McCubrey JA; Angus CW; Nutter JM; Sigounas G
Adv Biol Regul; 2014 Sep; 56():51-65. PubMed ID: 24933481
[TBL] [Abstract][Full Text] [Related]
12. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
13. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
[TBL] [Abstract][Full Text] [Related]
14. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
Di Mitri D; Mirenda M; Vasilevska J; Calcinotto A; Delaleu N; Revandkar A; Gil V; Boysen G; Losa M; Mosole S; Pasquini E; D'Antuono R; Masetti M; Zagato E; Chiorino G; Ostano P; Rinaldi A; Gnetti L; Graupera M; Martins Figueiredo Fonseca AR; Pereira Mestre R; Waugh D; Barry S; De Bono J; Alimonti A
Cell Rep; 2019 Aug; 28(8):2156-2168.e5. PubMed ID: 31433989
[TBL] [Abstract][Full Text] [Related]
15. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
[TBL] [Abstract][Full Text] [Related]
16. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
[TBL] [Abstract][Full Text] [Related]
17. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
18. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
[TBL] [Abstract][Full Text] [Related]
19. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
